Abstract

BACKGROUND: Extended-spectrum beta-lactamase (ESBL)-producing bacteria have resulted in vexatious problem to combat lower respiratory tract infection (LRTI). However, no detailed studies have been done in Nepal exploring the status of such pathogens from LRTI. Therefore, this study was carried out to assess the current levels of antimicrobial resistance with special reference to ESBL-producing respiratory bacterial pathogens in Nepal.METHODS: A prospective study was conducted at Tribhuvan University Teaching Hospital in the capital city of Nepal. Specimens representing lower respiratory tract were received from 1120 patients suspected of LRTI. The specimens were collected and processed according to standard methodology. Combination disk (CD) and disk synergy test (DST) methods were used for the detection of ESBL-producing isolates.RESULTS: Of the total 314 isolates belonging to Enterobacteriaceae and nonfermentative bacteria, 24.2% were ESBL-producers which included 42.2% of Klebsiella pneumoniae, 8.8% of Pseudomonas species, 41.9% of Escherichia coli, 12.9% of Acinetobacter species, 13.3% of Citrobacter species and 66.7% of Morganella morganii. ESBL-producers were more common among hospitalized patients. For ESBL-producers, the most effective drug was found to be imipenem, meropenem, followed by cefoperazone-sulbactam and amikacin.CONCLUSIONS: One-fourth of the isolates belonging to Enterobacteriaceae and non-fermentative bacteria were ESBL-producer. It is quite essential to have effective antimicrobial and infection control policy in the hospital and special steps should be taken to prevent clonal dissemination of the resistant strains. Further studies should be done in other hospitals of Nepal to know the phenotype and genotype of ESBL-producing isolates prevailing in our country.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call